oseltamivir has been researched along with gs 4071 in 131 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.76) | 18.2507 |
| 2000's | 18 (13.74) | 29.6817 |
| 2010's | 103 (78.63) | 24.3611 |
| 2020's | 9 (6.87) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XG; Chen, YL; Hu, ZD; Liu, MC; Lü, WJ; Luan, F; Ma, WP; Zhang, XY | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Breidenbach, A; Chu, T; Fowler, S; Funk, C; Hoffmann, G; Otteneder, MB; Prinssen, EP; Rayner, CR | 1 |
| Cheng, YS; Fang, JM; Lee, PS; Liu, KC; Wang, SY; Wong, CH | 1 |
| Beneduce, L; Cappelletti, L; Capua, I; Cattoli, G; De-Eknamkul, W; Fassina, G; Frecer, V; Gallotta, A; Jongaroonngamsang, N; Kongkamnerd, J; Miertus, S; Milani, A; Pengo, P; Prandi, A; Rojsitthisak, P; Rungrotmongkol, T; Seneci, P; Terregino, C | 1 |
| Belli, S; Funk, C; Heinig, K; Hoffmann, G; Lazic, SE; Otteneder, MB; Poirier, A; Portmann, R; Prinssen, E; Rayner, CR; Schuler, F; Singer, T; Smith, DE | 1 |
| Chen, CA; Chen, CL; Cheng, TJ; Cheng, YS; Fang, JM; Hsieh, WC; Hu, OY; Huang, PW; Jan, JT; Lin, WH; Shie, JJ; Tarbet, EB; Wang, SY; Weinheimer, S; Wong, CH | 1 |
| Clement, B; Koch, O; Kotthaus, J; Müller-Fielitz, H; Raasch, W; Riebling, L; Schade, D; Schmidtke, M; Seidel, N | 1 |
| Albiñana, CB; Konvalinka, J; Kožíšek, M; Machara, A; Pachl, P; Řezáčová, P | 1 |
| Abet, V; Alvarez-Builla, J; Burgos, C; Filace, F; Recio, J | 1 |
| Cheng, LP; Li, L; Pang, W; Wang, Z; Zhang, XH; Zhao, JL | 1 |
| Cheng, TJ; Cheng, YE; Chiu, DC; Fang, JM; Hsu, PH; Jan, JT; Lee, PS; Tsai, KC; Wu, KL | 1 |
| Cheng, LP; Fu, SK; Pang, W; Zheng, XS; Zhong, ZJ | 1 |
| He, G; Massarella, J; Ward, P | 1 |
| Citron, A; Clarke, T; Gray, D; Herron, W; Serpe, C; Wiltshire, B; Wiltshire, H | 1 |
| Barrett, J; Cihlar, T; Hill, G; Ho, ES; Liu, B; Oo, C; Prior, K; Ward, P; Wiltshire, H | 1 |
| Barrett, J; Dorr, A; Oo, C; Snell, P | 1 |
| Fujita, T; Kanai, M; Kusuhara, H; Ose, A; Shibasaki, M; Sugiyama, Y; Yamamoto, A; Yamatsugu, K | 1 |
| Arai, T; Hatori, A; Ito, G; Kato, K; Konno, F; Odawara, C; Ogawa, M; Suzuki, K; Yamasaki, T; Yanamoto, K; Zhang, MR | 1 |
| Bucheli, F; Heinig, K | 1 |
| Hosokawa, M; Ito, M; Kanai, M; Kusuhara, H; Ose, A; Schuetz, JD; Shibasaki, M; Sugiyama, Y; Yamatsugu, K | 1 |
| Accinelli, C; Fick, J; Lindberg, R; Olsen, B; Saccà, ML | 1 |
| Arai, T; Hatori, A; Kawamura, K; Konno, F; Nakao, R; Suzuki, K; Yamasaki, T; Yanamoto, K; Yui, J; Zhang, MR | 1 |
| Izumi, Y; Narahashi, T; O'Dell, K; Tokuda, K; Zorumski, C | 1 |
| Chang, Q; Chow, MS; Zuo, Z | 1 |
| Brown, A; Drusano, GL; Kulawy, R; McSharry, JJ; Weng, Q | 1 |
| Srinivas, NR | 1 |
| Barrett, J; Kirkpatrick, C; Lennon, S; Rayner, C | 1 |
| Kobayashi, D; Kuramochi, M; Nemoto, E; Oshima, S; Saitoh, Y | 1 |
| Brockhaus, M; Chu, T; Ebeling, M; Gatti, S; Jacobsen, H; Knoflach, F; Lindemann, L; Loetscher, H; Paulson, JC; Prinssen, E; Schuhbauer, D; Wettstein, JG | 1 |
| Ghosh, GC; Nakada, N; Tanaka, H; Yamashita, N | 2 |
| Davies, BE | 1 |
| Chen, P; Liu, XW; Ma, J; Ng, S; Than, A; Zeng, J; Zhang, J; Zhao, Y | 1 |
| Combes, A; Farinotti, R; Fernandez, C; Lemaitre, F; Luyt, CE; Nieszkowska, A; Roullet-Renoleau, F; Zahr, N | 1 |
| Arnason, JT; Foster, BC; Krantis, A; Liu, R; Mao, J; Saleem, A; Tam, TW | 1 |
| Govorkova, EA; Ilyushina, NA; Rehg, JE; Seiler, JP; Webster, RG | 1 |
| Ahsman, MJ; de Hoog, M; Fraaij, PL; Osterhaus, AD; Tibboel, D; Wildschut, ED | 1 |
| Fu, Y; Nie, Y; Yang, G; Yang, Z; Zhou, L; Zu, Y | 1 |
| Bhatt, PA; Bhavesh, D; Kanneti, R; Paramar, D; R, S | 1 |
| Aouri, M; Buclin, T; Decosterd, LA; Ivanyuk, A; Meylan, P; Widmer, N | 1 |
| Chappuy, H; Duchêne, P; Ducrocq, S; Giraud, C; Hubert, P; Manceau, S; Mogenet, A; Oualha, M; Treluyer, JM | 1 |
| Barr, JJ; Bond, PL; Singer, AC; Slater, FR; Turner, S | 1 |
| Bucheli, F; Gajate-Perez, A; Heinig, K; Wirz, T | 1 |
| Cao, YL; Guo, Y; Xiao, JH; Zhang, C; Zhong, W | 1 |
| Greer, LG; Leff, RD; McCracken, GH; Roberts, SW; Rogers, VL; Sheffield, JS; Wendel, GD | 1 |
| Beigi, RH; Caritis, SN; Clark, S; Easterling, T; Han, K; Hankins, GD; Hebert, MF; Mattison, DR; Ren, Z; Venkataramanan, R; Zajicek, A | 1 |
| Alpendurada, MF; Barceló, D; Gonçalves, C; Osorio, V; Pérez, S; Petrovic, M | 1 |
| Gut, H; Taylor, GL; Walsh, MA; Xu, G | 1 |
| Chiyoda, T; Inano, A; Kano, T; Kishimura, K; Kodama, N; Morimoto, K; Nagami, T; Ogama, Y; Ogihara, T; Shimada, R; Tamai, I; Toda, S; Yokoyama, M | 1 |
| Govorkova, EA; Marathe, BM; Prevost, A; Rehg, JE; Webster, RG | 1 |
| Babany, G; Hubert, D; Jullien, V; Launay, O; Lortholary, O; Sermet, I | 1 |
| Babu, YS; Bantia, S; Upshaw, R | 1 |
| Beneduce, L; Capua, I; Cattoli, G; De-Eknamkul, W; Fassina, G; Gallotta, A; Kongkamnerd, J; Miertus, S; Milani, A; Pengo, P; Terregino, C | 1 |
| Nafisi, S; Vishkaee, TS | 1 |
| Davies, B; Hoffmann, G; Koerner, A; Lave, T; Parrott, N; Prinssen, E; Singer, T; Theogaraj, E | 1 |
| Ohuchi, M; Ushirogawa, H | 1 |
| Lodise, TP; Pai, MP | 1 |
| Berveiller, P; Bonati, C; Duchene, P; Gil, S; Giraud, C; Mir, O; Treluyer, JM; Vinot, C | 1 |
| Aoki, FY; Jeffery, J; Lam, H; Sitar, DS | 1 |
| Dye, C; Leknes, H; Sturtzel, IE | 1 |
| Breidenbach, A; Freichel, C; Gand, L; Hoffmann, G; Körner, A; Prinssen, E; Singer, T; Toot, J; Weiser, T | 1 |
| Dotsikas, Y; Drakoulis, N; Karalis, V; Loukas, YL; Maltezou, HC; Siahanidou, T; Theodoridou, M; Zervaki, E | 1 |
| Bansod, S; Bellot, M; Breidenbach, A; Donner, B; Freichel, C; Gand, L; Gatti, S; Hoffmann, G; Körner, A; Prinssen, EP; Singer, T; Weiser, T | 1 |
| Antignac, M; Combes, A; Corvol, E; Farinotti, R; Fernandez, C; Lemaitre, F; Luyt, CE; Nieszkowska, A; Roullet-Renoleau, F; Zahr, N | 1 |
| Haji, A; Iwajima, Y; Kimura, S; Kurono, Y; Maeda, Y; Nagano, Y; Niwa, Y; Ohi, Y; Ono, H; Yamamoto, S | 1 |
| Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M; Schwab, M; Tarkiainen, EK | 1 |
| Ahmed, MS; Hankins, GD; Nanovskaya, TN; Patrikeeva, S; Zhan, Y | 1 |
| Aceves Baldó, P; Beryozkina, A; Brennan, BJ; Chappey, C; Cirrincione-Dall, G; Davies, B; Lennon-Chrimes, S; Morcos, PN; Rayner, CR | 1 |
| Herring, VL; Hu, ZY; Laizure, SC; Meibohm, B; Parker, RB | 1 |
| Azuma, T; Nakada, N; Tanaka, H; Yamashita, N | 2 |
| Kakinuma, C; Kano, T; Matsumoto, N; Morimoto, K; Nagami, T; Ogihara, T; Wada, S | 1 |
| Eyler, RF; Heung, M; Mueller, BA; Napolitano, LM; Park, PK; Pleva, M; Sowinski, KM | 1 |
| Hatakeyama, D; Hiasa, M; Isoda, Y; Kanai, M; Kimura, Y; Kirino, Y; Kishimoto, Y; Kuzuhara, T; Saitoh, K; Shibasaki, M | 1 |
| Mohajerani, N; Nafisi, S; Vishkaee, TS | 1 |
| Harvey, C; Kidy, Z; Mulla, H; Peek, GJ; Ramaiah, R; Westrope, C | 1 |
| Cordero, KS; Rong, L; Tisoncik-Go, J | 1 |
| Chazono, K; Iwajima, Y; Maeda, Y; Nagano, Y; Ohsawa, M; Ono, H; Yamamoto, S | 1 |
| Beijnen, JH; de Lange, DW; Huitema, AD; Kromdijk, W; Sikma, MA; van den Broek, MP | 1 |
| Achenbach, JE; Bowen, RA | 1 |
| Blessborn, D; Hanpithakpong, W; Instiaty, I; Jittmala, P; Lindegardh, N; Pukrittayakamee, S; Tarning, J; White, NJ | 1 |
| Gao, F; Gao, GF; Jiang, H; Liu, Y; Qi, J; Qin, G; Vavricka, CJ; Wu, Y; Yu, K | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Kamal, MA; Rayner, CR; Reynolds, DK; Smith, PF; Subramoney, V; Van Wart, SA | 1 |
| Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Hammel, JP; Kamal, MA; Rayner, CR; Reynolds, DK; Smith, PF; Toovey, S; Van Wart, SA | 1 |
| Boucher, BA; Herring, VL; Hickerson, WL; Hu, ZY; Laizure, SC; Parker, RB | 1 |
| Bröjer, C; Gillman, A; Järhult, JD; Latorre-Margalef, N; Lindberg, RH; Muradrasoli, S; Nordh, J; Olsen, B; Söderström, H; Waldenström, J | 1 |
| Jiang, L; Liu, J; Lu, X; Tang, Y; Xi, X; Zhang, H; Zhu, J | 1 |
| Charunwattana, P; Day, NP; Hanpithakpong, W; Jittamala, P; Lawpoolsri, S; Lindegardh, N; Panapipat, S; Pukrittayakamee, S; Tarning, J; Taylor, WR; White, NJ | 1 |
| Battistini, L; Casiraghi, G; Curti, C; Dell'Amico, L; Kerry, PS; Pala, D; Pelosi, G; Rassu, G; Rivara, S; Sartori, A; Zanardi, F | 1 |
| Cai, L; Gao, D; Li, P; Liu, L; Ma, Y; Pan, H; Wang, C; Wang, H; Zhang, P; Zhang, Y | 1 |
| Chepurnov, AA; Cheresiz, SV; Davey, R; Dubich, TS; Kononova, AA; Kushch, AA; Pokrovsky, AG; Razumova, YV | 1 |
| Hatano, N; Iwajima, Y; Maeda, Y; Muraki, K; Muraki, Y; Ono, H; Suzuki, H | 1 |
| Edginton, AN; Hu, ZY; Laizure, SC; Parker, RB | 1 |
| Donnelly, RP; Ilyushina, NA | 1 |
| Huang, B; Liu, X; Ma, X; Qi, W; Shi, F; Xie, Y; Xu, D; Xu, W; Zhang, Y | 1 |
| Chintakrindi, AS; Chowdhary, AS; Deshmukh, RA; Gohil, DJ; Kanyalkar, MA; Kothari, ST; Meharunkar, R; Shinde, PS; Warke, RV | 1 |
| Brennan, BJ; Gibiansky, L; Giraudon, M; Kamal, MA; Rayner, CR; Robson, R; Subramoney, V | 1 |
| Lindh, M; Norberg, P; Olofsson, S | 1 |
| Hiromura, M; Honda, S; Inoue, K; Kosako, K; Kuroki, H; Shiratani, T; Soeda, S; Toda, A; Uchiyama, H | 1 |
| Beigi, RH; Caritis, SN; Clark, S; Easterling, TR; Han, K; Hankins, GD; Hebert, MF; Pillai, VC; Ren, Z; Venkataramanan, R; Zajicek, A | 1 |
| Bröjer, C; Daggfeldt, A; Gillman, A; Järhult, JD; Muradrasoli, S; Nykvist, M; Olsen, B; Söderström, H; Waldenström, J; Wille, M | 1 |
| Azuma, T; Inoyama, T; Ishiuchi, H; Mino, Y; Sato, T; Tanaka, H; Teranishi, Y; Yamaoka, M; Yamashita, N | 1 |
| Hu, HY; Niu, LX; Sun, MC; Wang, C; Wang, WL; Wang, ZM; Wu, QY | 1 |
| Clinch, B; Gibiansky, L; Kamal, MA; Lien, KY; Rayner, CR; Robson, R; Subramoney, V | 1 |
| Pawar, SD; Tare, DS | 1 |
| Forrest, A; Govorkova, EA; Marathe, BM; Nie, J; Pamulapati, C; Rao, G; Rayner, CR; Reddy, MB; Yang, KH | 1 |
| Dou, J; Jin, J; Li, M; Wang, D; Wang, H; Xu, J; Yu, J; Zhou, C | 1 |
| Chairat, K; Day, NP; Hanpithakpong, W; Jittamala, P; Pukrittayakamee, S; Tarning, J; White, NJ | 1 |
| Brennan, BJ; Frey, N; Kamal, MA; Lien, YT; Morcos, PN; Rayner, CR; Subramoney, V | 1 |
| Couet, W; Galindo Bedor, DC; Lamarche, I; Laroche, J; Marchand, S; Pereira de Santana, D | 1 |
| Fujita, T; Horita, S; Ito, M; Kondo, T; Kusuhara, H; Nakayama, H; Ose, A; Sugiyama, Y; Tanabe, K | 1 |
| Ding, G; Huang, W; Li, Z; Meng, Y; Meng, Z; Shen, W; Wang, Z; Xiao, W; Xu, J; Xu, S | 1 |
| Cho, JY; Jang, IJ; Lee, H; Lee, S; Lim, KS; Oh, J; Yoon, SH; Yu, KS | 1 |
| Angioletti-Uberti, S; Bardua, M; Bhatia, S; Böttcher, C; Budt, M; Haag, R; Hamann, A; Herrmann, A; Hoffmann, U; Lauster, D; Ludwig, K; Paulus, F; Popp, N; Stadtmüller, M; Wolff, T | 1 |
| Chen, WS; Gao, SH; Miao, HJ; Wang, ZP; Wen, Y; Yun, YL | 1 |
| Ahn, SJ; Baek, YH; Chae, HB; Choi, WS; Choi, YK; Govorkova, EA; Hwang, J; Jeong, JH; Kim, CJ; Kim, MH; Kwon, HI; Kwon, JJ; Lloren, KKS; Song, MS; Webby, RJ | 1 |
| Kolodziej, H; Quosdorf, S; Schuetz, A | 1 |
| Bae, MA; Go, YY; Jang, Y; Kim, M; Kim, SS; Ku, KB; Kwon, OS; Shin, D; Shin, JS; Yoon, YS | 1 |
| Chang, YT; Huang, MF; Liang, SS; Lin, YR; Shiue, YL | 1 |
| Deleu, S; Hillewaert, V; Hoetelmans, RMW; Kakuda, TN; Leopold, L; Lwin, A; Spittaels, K; Vercauteren, JJ | 1 |
| Liu, GJ; Wang, B; Wang, S; Xing, GW; Yang, X; Zhang, Y | 1 |
| Brillault, J; Carrez, R; Couet, W; Grégoire, N; Lamarche, I; Laroche, J; Marchand, S | 1 |
| Basavarajappa, M; Beland, FA; Fisher, J; Gamboa da Costa, G; Loukotková, L; Lumen, A; Mattison, D; Morris, SM; Roberts, R | 1 |
| Bhardwaj, R; Clinch, B; Gibiansky, L; Grimsey, P; Parrott, NJ; Ravva, P; Sturm, S; Zwanziger, E | 1 |
| Chen, Y; Ke, M; Lin, C; Xu, J | 1 |
| Fujiwara, K; Matsufuji, S; Saita, T; Yamamoto, Y | 1 |
| Castro, A; Deng, R; Hanley, WD; Horn, P; Kulkarni, P; Lim, JJ; Maia, M; McBride, JM; Newton, E; Peck, MC; She, G; Tavel, JA | 1 |
| Bertagnin, C; Bonomini, A; Huang, B; Jia, H; Jia, R; Jiang, Y; Liu, C; Liu, X; Loregian, A; Lucca, C; Ma, X; Shi, F; Zhan, P; Zhang, J | 1 |
| Agarwal, V; Bröjer, C; Ellström, P; Järhult, JD; Lundkvist, Å; Naguib, MM; Nykvist, M; Skog, E; Westman, G; Wille, M | 1 |
| Bertagnin, C; Bonomini, A; Guizzo, L; Huang, B; Jia, H; Jia, R; Jia, S; Jiang, Y; Liu, C; Liu, X; Loregian, A; Ma, X; Zhan, P; Zhang, J; Zhang, X | 1 |
6 review(s) available for oseltamivir and gs 4071
| Article | Year |
|---|---|
Prodrug approach: An overview of recent cases.
Topics: Absorption, Physicochemical; Animals; Cell Membrane Permeability; Drug Discovery; Humans; Prodrugs; Solubility; Water | 2017 |
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
Topics: Acetamides; Animals; Antiviral Agents; Enzyme Inhibitors; Humans; Neuraminidase; Oseltamivir; Prodrugs | 1999 |
Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomedical Research; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Drug Combinations; Drug Discovery; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Humans; Membrane Transport Modulators; Nelfinavir; Organic Anion Transport Protein 1; Oseltamivir; Pharmacology, Clinical; Taxoids | 2009 |
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
Topics: Administration, Oral; Antiviral Agents; Biological Availability; Drug Interactions; Humans; Influenza, Human; Oseltamivir; Prodrugs | 2010 |
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Topics: Antiviral Agents; Area Under Curve; Disease Outbreaks; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza Vaccines; Influenza, Human; Oseltamivir; Pandemics; Prodrugs; United States | 2010 |
Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Area Under Curve; Body Weight; Child; Child, Preschool; Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Infant; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Theoretical; Oseltamivir; Predictive Value of Tests; Young Adult | 2013 |
16 trial(s) available for oseltamivir and gs 4071
| Article | Year |
|---|---|
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Topics: Acetamides; Adolescent; Adult; Amoxicillin; Animals; Antiviral Agents; Biological Transport; CHO Cells; Cimetidine; Cricetinae; Cross-Over Studies; Drug Interactions; Female; Humans; Influenza, Human; Kidney; Male; Middle Aged; Neuraminidase; Organic Anion Transport Protein 1; Oseltamivir; p-Aminohippuric Acid; Probenecid; Prodrugs | 2002 |
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Topics: Acetamides; Administration, Oral; Adult; Aluminum Hydroxide; Analysis of Variance; Antacids; Antiviral Agents; Calcium Carbonate; Cross-Over Studies; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Influenza, Human; Magnesium Hydroxide; Male; Middle Aged; Oseltamivir; Prodrugs; Tablets; Therapeutic Equivalency | 2002 |
Oseltamivir oral suspension and capsules are bioequivalent for the active metabolite in healthy adult volunteers.
Topics: Adult; Antiviral Agents; Area Under Curve; Capsules; Cross-Over Studies; Humans; Oseltamivir; Suspensions; Therapeutic Equivalency | 2009 |
Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers.
Topics: Acetamides; Adult; Animals; Antiviral Agents; Area Under Curve; Cross-Over Studies; Food-Drug Interactions; Half-Life; Humans; Milk; Oseltamivir; Reference Values | 2011 |
Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.
Topics: Adolescent; Adult; Antiviral Agents; Cystic Fibrosis; Female; Humans; Male; Oseltamivir; Sputum; Young Adult | 2011 |
Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
Topics: Adult; Antiviral Agents; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Obesity; Oseltamivir; Treatment Outcome; Young Adult | 2011 |
Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
Topics: Adult; Aged; Antiviral Agents; Biotransformation; Cohort Studies; Cross-Over Studies; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Immunosuppressive Agents; Influenza, Human; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Neuraminidase; Oseltamivir; Tacrolimus; Young Adult | 2011 |
Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antiviral Agents; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Injections, Intravenous; Male; Middle Aged; Oseltamivir; Placebos | 2012 |
Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support.
Topics: Adult; Antiviral Agents; Area Under Curve; Creatinine; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Nonlinear Dynamics; Oseltamivir; Tissue Distribution | 2013 |
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
Topics: Adult; Antiviral Agents; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Male; Multivariate Analysis; Neuraminidase; Oseltamivir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding; Young Adult | 2013 |
Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.
Topics: Administration, Oral; Adult; Antiviral Agents; Body Mass Index; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Obesity; Oseltamivir; Thailand; Young Adult | 2014 |
Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.
Topics: Adolescent; Adult; Antiviral Agents; Computer Simulation; Female; Humans; Middle Aged; Models, Biological; Oseltamivir; Pregnancy; Young Adult | 2015 |
Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.
Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Models, Biological; Obesity; Oseltamivir; Volunteers; Young Adult | 2016 |
Bioequivalence of two oseltamivir formulations in healthy Chinese volunteers
.
Topics: Adult; Area Under Curve; Asian People; Biological Availability; Capsules; Chemistry, Pharmaceutical; Cross-Over Studies; Drugs, Generic; Healthy Volunteers; Humans; Male; Oseltamivir; Therapeutic Equivalency; Young Adult | 2017 |
Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy v
Topics: Adolescent; Adult; Antiviral Agents; Area Under Curve; Cross-Over Studies; Diarrhea; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Oseltamivir; Pyridines; Pyrimidines; Pyrroles; Time Factors; Young Adult | 2018 |
Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiviral Agents; Drug Therapy, Combination; Half-Life; Humans; Influenza A virus; Influenza, Human; Infusions, Intravenous; Inpatients; Middle Aged; Nasopharynx; Oseltamivir; Trachea | 2020 |
109 other study(ies) available for oseltamivir and gs 4071
| Article | Year |
|---|---|
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
Topics: Enzyme Inhibitors; Linear Models; Models, Biological; Neuraminidase; Quantitative Structure-Activity Relationship | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.
Topics: Aged; Aged, 80 and over; Animals; Antiviral Agents; Biological Transport, Active; Brain; Carboxylesterase; Female; Humans; Liver; Male; Nucleotidyltransferases; Oseltamivir; Rats; Rats, Sprague-Dawley | 2009 |
Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Topics: Administration, Oral; Antiviral Agents; Carbon Dioxide; Cell Line; Drug Evaluation, Preclinical; Enzyme Inhibitors; Esters; Guanidine; Humans; Hydrophobic and Hydrophilic Interactions; Influenza A virus; Influenza, Human; Ions; Molecular Structure; Naphthols; Neuraminidase; Oseltamivir; Prodrugs; Zanamivir | 2011 |
Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus.
Topics: Animals; Antiviral Agents; Binding Sites; Birds; Influenza A virus; Influenza A Virus, H7N1 Subtype; Influenza A Virus, H7N3 Subtype; Influenza in Birds; Models, Molecular; Neuraminidase; Oseltamivir | 2012 |
Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies.
Topics: Animals; Antiviral Agents; CHO Cells; Cricetinae; Cricetulus; In Vitro Techniques; Intestinal Mucosa; Male; Oseltamivir; Peptide Transporter 1; Rats; Rats, Sprague-Dawley; Symporters | 2012 |
Development of oseltamivir phosphonate congeners as anti-influenza agents.
Topics: Acetamides; Administration, Oral; Alphainfluenzavirus; Animals; Antiviral Agents; Betainfluenzavirus; Biological Availability; Blood Proteins; Cyclohexenes; Cytopathogenic Effect, Viral; Dogs; Drug Resistance, Viral; Drug Stability; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phosphorous Acids; Protein Binding; Rats; Structure-Activity Relationship | 2012 |
Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.
Topics: Administration, Oral; Amidines; Animals; Antiviral Agents; Biological Availability; Dogs; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Prodrugs; Protein Binding; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Swine | 2014 |
Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza.
Topics: Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Kinetics; Neuraminidase; Oseltamivir; Pandemics; Phosphorous Acids; Protein Binding; Thermodynamics | 2016 |
Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
Topics: Antiviral Agents; Binding Sites; Drug Design; Enzyme Inhibitors; Humans; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Inhibitory Concentration 50; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Protein Structure, Tertiary; Quantitative Structure-Activity Relationship | 2017 |
Acylguanidine derivatives of zanamivir and oseltamivir: Potential orally available prodrugs against influenza viruses.
Topics: Administration, Oral; Antiviral Agents; Dose-Response Relationship, Drug; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Orthomyxoviridae; Oseltamivir; Prodrugs; Structure-Activity Relationship; Zanamivir | 2018 |
Design, synthesis and biological evaluation of dihydrofurocoumarin derivatives as potent neuraminidase inhibitors.
Topics: Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Furocoumarins; Humans; Molecular Dynamics Simulation; Molecular Structure; Neuraminidase; Structure-Activity Relationship | 2021 |
Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.
Topics: Acetamides; Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Humans; Influenza, Human; Mass Spectrometry; Oseltamivir; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2000 |
P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Topics: Acetamides; Acridines; Animals; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Cell Line; Dogs; LLC-PK1 Cells; Male; Mice; Mice, Knockout; Oseltamivir; Prodrugs; Rats; Rats, Wistar; RNA, Messenger; Swine; Tetrahydroisoquinolines | 2008 |
Radiosyntheses of two positron emission tomography probes: [11C]Oseltamivir and its active metabolite [11C]Ro 64-0802.
Topics: Acetamides; Animals; Brain; Carbon Radioisotopes; Isotope Labeling; Mice; Oseltamivir; Positron-Emission Tomography; Radiopharmaceuticals | 2008 |
Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry.
Topics: Animals; Brain Chemistry; Chromatography, Liquid; Humans; Oseltamivir; Rats; Reproducibility of Results; Tandem Mass Spectrometry; Uncertainty | 2008 |
Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion t
Topics: Acetamides; Adhesins, Escherichia coli; Animals; Antiviral Agents; Biological Transport; Blood-Brain Barrier; Brain; Cells, Cultured; Female; Gene Knockout Techniques; Humans; Male; Mice; Multidrug Resistance-Associated Proteins; Organic Anion Transporters, Sodium-Independent; Oseltamivir; Physiological Phenomena; Tissue Distribution | 2009 |
Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems.
Topics: Antiviral Agents; Biodegradation, Environmental; Ecosystem; Environmental Monitoring; Oseltamivir; Rivers; Soil Microbiology; Water Pollutants, Chemical | 2009 |
Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice.
Topics: Acetamides; Animals; Antiviral Agents; Brain; Carbon Radioisotopes; Male; Mice; Orthomyxoviridae; Oseltamivir; Positron-Emission Tomography; Tissue Distribution | 2009 |
Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants.
Topics: Animals; Antiviral Agents; Behavior, Animal; Caffeine; Central Nervous System Stimulants; Drug Interactions; Enzyme Inhibitors; Ephedrine; Ethanol; Excitatory Postsynaptic Potentials; Hippocampus; Locomotion; Long-Term Synaptic Depression; Male; Neuraminidase; Oseltamivir; Rats; Rats, Sprague-Dawley; Risk Assessment; Time Factors | 2008 |
Studies on the influence of esterase inhibitor to the pharmacokinetic profiles of oseltamivir and oseltamivir carboxylate in rats using an improved LC/MS/MS method.
Topics: Animals; Cholinesterase Inhibitors; Chromatography, Liquid; Dichlorvos; Humans; Hydrolysis; Male; Oseltamivir; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2009 |
Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.
Topics: Animals; Antiviral Agents; Area Under Curve; Cell Line; Dogs; Dose-Response Relationship, Drug; Influenza A Virus, H3N2 Subtype; Microbial Sensitivity Tests; Models, Biological; Oseltamivir | 2009 |
Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice.
Topics: Animals; Antiviral Agents; Blood-Brain Barrier; Brain; Evans Blue; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oseltamivir | 2009 |
In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite.
Topics: Animals; Antiviral Agents; Enzyme Inhibitors; Humans; Influenza A Virus, H3N2 Subtype; Neuraminidase; Oseltamivir; Phosphates; Primates; Prodrugs; Rats; Substrate Specificity | 2010 |
Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan.
Topics: Antiviral Agents; Chromatography, Liquid; Drug Residues; Drug Resistance, Viral; Environmental Health; Environmental Monitoring; Fresh Water; Humans; Influenza, Human; Japan; Orthomyxoviridae; Oseltamivir; Rivers; Seasons; Sewage; Tandem Mass Spectrometry; Water Pollutants, Chemical; Water Purification | 2010 |
Sugar-based synthesis of Tamiflu and its inhibitory effects on cell secretion.
Topics: Animals; Antiviral Agents; Calcium Gluconate; Humans; Influenza, Human; Oseltamivir; PC12 Cells; Rats; Synaptic Transmission | 2010 |
Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation.
Topics: Antiviral Agents; Biological Availability; Extracorporeal Membrane Oxygenation; Female; Hemofiltration; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Respiratory Distress Syndrome; Young Adult | 2010 |
The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir.
Topics: Antiviral Agents; Biological Products; Chromatography, High Pressure Liquid; Female; Fluorometry; Herb-Drug Interactions; Humans; Male; Medicine, Chinese Traditional; Microsomes, Liver; Oseltamivir; Plant Extracts; Prodrugs; Spectrometry, Mass, Electrospray Ionization | 2010 |
Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Topics: Animals; Antiviral Agents; Cell Line; Crystallography; Disease Models, Animal; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Ferrets; Humans; Influenza A Virus, H5N1 Subtype; Kidney; Male; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Structure, Tertiary; Recombinant Proteins; Zanamivir | 2010 |
Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support.
Topics: Adolescent; Antiviral Agents; Area Under Curve; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Oseltamivir; Prospective Studies | 2010 |
Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants.
Topics: Amantadine; Antiviral Agents; Chromatography, Liquid; Environmental Monitoring; Oseltamivir; Ozone; Sewage; Tandem Mass Spectrometry; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Pollution, Chemical | 2010 |
Synergistic effects in the designs of neuraminidase ligands: analysis from docking and molecular dynamics studies.
Topics: Acids, Carbocyclic; Benzoates; Catalytic Domain; Cyclohexenes; Cyclopentanes; Drug Design; Guanidines; Humans; Hydrogen Bonding; Influenza, Human; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Static Electricity; Structure-Activity Relationship; Thermodynamics | 2010 |
Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies.
Topics: Chromatography, Liquid; Drug Stability; Humans; Least-Squares Analysis; Oseltamivir; Phosphates; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Critical Illness; Female; Humans; Infant; Influenza, Human; Intensive Care Units; Intubation, Gastrointestinal; Male; Oseltamivir; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu®) and loss of nutrient removal performance.
Topics: Anti-Bacterial Agents; Antiviral Agents; Bacteria; Biodegradation, Environmental; Bioreactors; Microbial Consortia; Models, Biological; Oseltamivir; Pandemics; Particle Size; Phosphorus; Sewage; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Purification | 2011 |
Determination of oseltamivir (Tamiflu®) and oseltamivir carboxylate in dried blood spots using offline or online extraction.
Topics: Analytic Sample Preparation Methods; Animals; Blood Chemical Analysis; Blood Specimen Collection; Chemical Fractionation; Chromatography, Liquid; Chromatography, Thin Layer; Humans; Male; Online Systems; Oseltamivir; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry | 2011 |
[Establishment of a cell-based 2009 H1N1 influenza neuraminidase inhibitors evaluation system].
Topics: Cell Line, Tumor; Drug Resistance, Viral; Enzyme Inhibitors; HEK293 Cells; Hemagglutinin Glycoproteins, Influenza Virus; HIV-1; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Mutation; Neuraminidase; Oseltamivir; Plasmids; Transfection; Virus Internalization | 2010 |
Pharmacokinetics of oseltamivir according to trimester of pregnancy.
Topics: Adolescent; Adult; Antiviral Agents; Area Under Curve; Female; Half-Life; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Maximum Allowable Concentration; Oseltamivir; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Time Factors; Young Adult | 2011 |
Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antiviral Agents; Area Under Curve; Case-Control Studies; Female; Humans; Influenza, Human; Metabolic Clearance Rate; Oseltamivir; Pregnancy; Pregnancy Complications, Infectious; Young Adult | 2011 |
Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence.
Topics: Environmental Monitoring; Kinetics; Oseltamivir; Photochemical Processes; Solar Energy; Water Pollutants, Chemical | 2011 |
Structural basis for Streptococcus pneumoniae NanA inhibition by influenza antivirals zanamivir and oseltamivir carboxylate.
Topics: Animals; Antiviral Agents; Carboxylic Acids; Humans; Isoenzymes; Mice; Molecular Sequence Data; Molecular Structure; Neuraminidase; Oseltamivir; Protein Conformation; Streptococcus pneumoniae; Zanamivir | 2011 |
Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Drug Resistance, Viral; Female; Ferrets; Influenza A Virus, H1N1 Subtype; Lung; Microbial Sensitivity Tests; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Oxygen; Pneumonia, Viral; Viral Load; Viral Plaque Assay; Virus Replication | 2011 |
Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme.
Topics: Acids, Carbocyclic; Antiviral Agents; Buffers; Cyclopentanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Protein Binding; Solutions; Spectrometry, Fluorescence; Viral Proteins | 2011 |
A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system.
Topics: Baculoviridae; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Influenza A Virus, H7N1 Subtype; Influenza A Virus, H7N3 Subtype; Kinetics; Neuraminidase; Oseltamivir; Structure-Activity Relationship | 2012 |
Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin.
Topics: Binding Sites; Humans; Oseltamivir; Protein Binding; Protein Structure, Secondary; Serum Albumin; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2011 |
Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
Topics: Animals; Antiviral Agents; Computer Simulation; Enzyme Inhibitors; Haplorhini; Humans; Models, Biological; Neuraminidase; Oseltamivir; Prodrugs | 2011 |
Novel antiviral activity of neuraminidase inhibitors against an avian influenza a virus.
Topics: Animals; Antiviral Agents; Cell Line; Chickens; Dogs; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Microscopy, Electron, Scanning; Neuraminidase; Oseltamivir; Virion; Virus Assembly; Zanamivir | 2011 |
Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model.
Topics: Antiviral Agents; Female; Fetus; Humans; Maternal-Fetal Exchange; Oseltamivir; Placenta; Pregnancy; Prodrugs | 2012 |
Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic.
Topics: Chromatography, Liquid; Environmental Monitoring; Epidemiological Monitoring; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Molecular Structure; Norway; Oseltamivir; Pandemics; Sewage; Waste Disposal, Fluid; Water Pollutants, Chemical | 2012 |
Lack of unwanted effects of oseltamivir carboxylate in juvenile rats after subcutaneous administration.
Topics: Age Factors; Animals; Antiviral Agents; Area Under Curve; Female; Injections, Subcutaneous; Male; Oseltamivir; Rats; Rats, Sprague-Dawley; Sex Factors | 2012 |
Safety and pharmacokinetics of oseltamivir for prophylaxis of neonates exposed to influenza H1N1.
Topics: Antiviral Agents; Chemoprevention; Female; Humans; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir | 2012 |
Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat.
Topics: Administration, Oral; Animals; Antiviral Agents; Body Temperature; Body Weight; Brain; Central Nervous System; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Hypothermia; Male; Oseltamivir; Rats; Rats, Sprague-Dawley | 2012 |
Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.
Topics: Acute Kidney Injury; Adult; Antiviral Agents; Area Under Curve; Critical Illness; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; Female; Hemodiafiltration; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Oseltamivir; Pandemics; Respiratory Distress Syndrome; Young Adult | 2012 |
High doses of oseltamivir phosphate induce acute respiratory arrest in anaesthetized rats.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Humans; Influenza, Human; Male; Oseltamivir; Rats; Rats, Wistar; Respiration; Respiration, Artificial; Respiratory Insufficiency; Respiratory Rate; Vagotomy | 2012 |
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.
Topics: Adult; Antiviral Agents; Area Under Curve; Carboxylic Ester Hydrolases; Dose-Response Relationship, Drug; Drug Monitoring; Female; Genotype; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Male; Oseltamivir; Polymorphism, Genetic; Prodrugs | 2012 |
Transplacental transfer of oseltamivir carboxylate.
Topics: Antiviral Agents; Biological Transport; Cells, Cultured; Diffusion; Female; Humans; Maternal-Fetal Exchange; Organ Culture Techniques; Oseltamivir; Perfusion; Placenta; Pregnancy; Term Birth; Tissue Distribution | 2012 |
Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: improved applicabili
Topics: Chromatography, High Pressure Liquid; Humans; Oseltamivir; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2013 |
Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Environmental Monitoring; Humans; Influenza, Human; Japan; Oseltamivir; Rivers; Sewage; Water Pollutants, Chemical; Zanamivir | 2012 |
Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats.
Topics: Acetamides; Animals; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Male; Oseltamivir; Rats; Rats, Wistar; Tissue Distribution | 2012 |
Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
Topics: Academic Medical Centers; Adolescent; Adult; Antiviral Agents; Area Under Curve; Critical Illness; Extracorporeal Membrane Oxygenation; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Prospective Studies; Renal Dialysis; Time Factors | 2012 |
Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir.
Topics: Animals; Antiviral Agents; Behavior, Animal; Humans; Mice; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oseltamivir; Prodrugs; Video Recording | 2013 |
A comparative study of the interaction of Tamiflu and Oseltamivir carboxylate with bovine serum albumin.
Topics: Oseltamivir; Prodrugs; Protein Structure, Secondary; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2013 |
Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.
Topics: Cell Line; Drug Resistance, Viral; Hemagglutination; Humans; Lentivirus; Mutagenesis, Site-Directed; Neuraminidase; Orthomyxoviridae; Oseltamivir | 2013 |
Reduction in sympathetic nerve activity as a possible mechanism for the hypothermic effect of oseltamivir, an anti-influenza virus drug, in normal mice.
Topics: Animals; Antiviral Agents; Body Temperature; Hexamethonium; Hypothermia; Injections, Intraperitoneal; Injections, Intraventricular; Male; Mecamylamine; Mice; Neuraminidase; Nicotine; Oseltamivir; Zanamivir | 2013 |
Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique.
Topics: Adult; Aged; Antiviral Agents; Area Under Curve; Critical Illness; Female; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics | 2013 |
Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Ducks; Environmental Pollutants; Influenza A Virus, H5N2 Subtype; Influenza in Birds; Mutation; Neuraminidase; Oseltamivir; Viral Load; Viral Proteins; Virus Replication | 2013 |
Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers.
Topics: Antiviral Agents; Capillaries; Female; Humans; Male; Oseltamivir; Plasma | 2013 |
Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding.
Topics: Amino Acid Sequence; Computer Simulation; Drug Design; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H2N2 Subtype; Influenza A Virus, H3N2 Subtype; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Protein Conformation | 2013 |
Mass balance of anti-influenza drugs discharged into the Yodo River system, Japan, under an influenza outbreak.
Topics: Amantadine; Antiviral Agents; Disease Outbreaks; Environmental Monitoring; Humans; Influenza, Human; Japan; Oseltamivir; Rivers; Water Pollutants, Chemical | 2013 |
Nonvolatile salt-free stabilizer for the quantification of polar imipenem and cilastatin in human plasma using hydrophilic interaction chromatography/quadrupole mass spectrometry with contamination sensitive off-axis electrospray.
Topics: Acetonitriles; Chromatography, Liquid; Cilastatin; Humans; Hydrophobic and Hydrophilic Interactions; Imipenem; Linear Models; Methanol; Oseltamivir; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2013 |
Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir.
Topics: Animals; Anseriformes; Antiviral Agents; Chick Embryo; Computational Biology; Drug Resistance, Viral; Hemagglutinin Glycoproteins, Influenza Virus; Influenza A virus; Influenza in Birds; Male; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Water; Zanamivir | 2013 |
Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation.
Topics: Administration, Inhalation; Animals; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dry Powder Inhalers; Lactose; Leucine; Liposomes; Mannitol; Mass Spectrometry; Oseltamivir; Particle Size; Phosphates; Powders; Rats; X-Ray Diffraction | 2015 |
Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate.
Topics: Antiviral Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Oseltamivir; Structure-Activity Relationship | 2014 |
Noninvasive visualization of respiratory viral infection using bioorthogonal conjugated near-infrared-emitting quantum dots.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Female; HEK293 Cells; Humans; Influenza A Virus, H5N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Nanotechnology; Oseltamivir; Powders; Quantum Dots; Spectrometry, Fluorescence; Spectroscopy, Near-Infrared; Tissue Distribution; Virus Diseases | 2014 |
A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus.
Topics: Antibodies, Neutralizing; Antibodies, Viral; Chimera; HEK293 Cells; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H5N1 Subtype; Neuraminidase; Oseltamivir; Vesicular Stomatitis; Vesicular stomatitis Indiana virus | 2014 |
Oseltamivir blocks human neuronal nicotinic acetylcholine receptor-mediated currents.
Topics: Acetylcholine; Antiviral Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Neuroblastoma; Neurons; Nicotine; Nicotinic Agonists; Oseltamivir; Patch-Clamp Techniques; Receptors, Nicotinic | 2015 |
Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.
Topics: Adult; Antiviral Agents; Carboxylic Ester Hydrolases; Computer Simulation; Humans; Male; Models, Biological; Oseltamivir; Polymorphism, Genetic | 2014 |
In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate.
Topics: Antiviral Agents; Drug Therapy, Combination; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Interferon-beta; Interferons; Interleukins; Oseltamivir | 2014 |
Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Topics: Antiviral Agents; Binding Sites; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Structure-Activity Relationship; Viral Proteins | 2014 |
Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Topics: Amantadine; Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Humans; India; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Mutation; Nasopharynx; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Viral Matrix Proteins | 2015 |
Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Biological Availability; Female; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Oseltamivir; Young Adult | 2015 |
Published sequences do not support transfer of oseltamivir resistance mutations from avian to human influenza A virus strains.
Topics: Animals; Antiviral Agents; Birds; Drug Resistance, Viral; Humans; Influenza A virus; Influenza in Birds; Influenza, Human; Mutation; Neuraminidase; Oseltamivir; Phylogeny; Water Pollutants, Chemical | 2015 |
Effect of adenosine system in the action of oseltamivir on behavior in mice.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Animals; Antiviral Agents; Behavior, Animal; Caffeine; Dose-Response Relationship, Drug; Drug Interactions; Male; Mice; Neuraminidase; Oseltamivir; Phenethylamines; Pyrimidines; Receptors, Adenosine A2; Triazoles; Walking | 2015 |
Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.
Topics: Animals; Ducks; Influenza A Virus, H7N9 Subtype; Neuraminidase; Oseltamivir; Water | 2015 |
Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Cities; Cyclopentanes; Drug Residues; Environmental Monitoring; Guanidines; Japan; Limit of Detection; Oseltamivir; Ozone; Pyrans; Risk Assessment; Rivers; Sewage; Sialic Acids; Water Pollutants, Chemical; Water Purification; Zanamivir | 2015 |
Adsorption removal of antiviral drug oseltamivir and its metabolite oseltamivir carboxylate by carbon nanotubes: Effects of carbon nanotube properties and media.
Topics: Adsorption; Antiviral Agents; Carboxylic Acids; Environmental Pollutants; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Models, Theoretical; Nanotubes, Carbon; Oseltamivir | 2015 |
Investigating clinically adequate concentrations of oseltamivir carboxylate in end-stage renal disease patients undergoing hemodialysis using a population pharmacokinetic approach.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Models, Theoretical; Oseltamivir; Renal Dialysis; Young Adult | 2015 |
Use of embryonated chicken egg as a model to study the susceptibility of avian influenza H9N2 viruses to oseltamivir carboxylate.
Topics: Animals; Antiviral Agents; Chick Embryo; India; Influenza A Virus, H9N2 Subtype; Influenza in Birds; Inhibitory Concentration 50; Microbial Sensitivity Tests; Oseltamivir; Poultry; Viral Load | 2015 |
Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
Topics: Administration, Oral; Animals; Antiviral Agents; Ferrets; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Male; Models, Biological; Monte Carlo Method; Oseltamivir | 2015 |
Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
Topics: A549 Cells; Acute Lung Injury; Animals; Antiviral Agents; Benzoates; DNA-Directed RNA Polymerases; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Viral; HEK293 Cells; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Madin Darby Canine Kidney Cells; Male; Mice; Mice, Inbred ICR; Orthomyxoviridae Infections; Oseltamivir; Ribavirin; Virus Replication | 2016 |
Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Computer Simulation; Drug Administration Schedule; Female; Glycoside Hydrolase Inhibitors; Humans; Influenza, Human; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neuraminidase; Nonlinear Dynamics; Oseltamivir; Randomized Controlled Trials as Topic; Severity of Illness Index; Young Adult | 2015 |
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate.
Topics: Administration, Inhalation; Administration, Intravenous; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Area Under Curve; Bronchoalveolar Lavage; Male; Oseltamivir; Rats; Rats, Sprague-Dawley | 2016 |
Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.
Topics: Acetamides; Animals; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Brain; Computer Simulation; HEK293 Cells; Humans; Kidney; Mice, Knockout; Models, Biological; Monte Carlo Method; Mutation; Organic Anion Transporters, Sodium-Independent; Oseltamivir; Prodrugs; Random Allocation; Species Specificity; Tissue Distribution | 2017 |
Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.
Topics: Animals; Antiviral Agents; Binding Sites; Cell Survival; Dogs; Drug Design; Enzyme Inhibitors; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Structure, Tertiary; Structure-Activity Relationship; Virus Replication | 2017 |
The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.
Topics: Adult; Alleles; Antiviral Agents; Carboxylic Ester Hydrolases; Genotype; Humans; Influenza, Human; Male; Oseltamivir; Pharmacogenetics; Polymorphism, Single Nucleotide; Tandem Mass Spectrometry; Young Adult | 2017 |
Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo.
Topics: Analysis of Variance; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Dogs; Drug Synergism; Enzyme Inhibitors; Glycerol; Humans; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H7N1 Subtype; Influenza in Birds; Influenza, Human; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mice; Models, Statistical; Nanoparticles; Oseltamivir; Polymers; Poultry; Sialic Acids | 2017 |
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mutagenesis; Neuraminidase; Orthomyxoviridae; Oseltamivir; Reverse Genetics; Zanamivir | 2018 |
Different Inhibitory Potencies of Oseltamivir Carboxylate, Zanamivir, and Several Tannins on Bacterial and Viral Neuraminidases as Assessed in a Cell-Free Fluorescence-Based Enzyme Inhibition Assay.
Topics: Anti-Bacterial Agents; Antiviral Agents; Drug Synergism; Enzyme Assays; Hydrolyzable Tannins; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Tannins; Vibrio cholerae; Viral Proteins; Zanamivir | 2017 |
Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate.
Topics: Animals; Antiviral Agents; Female; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Lung; Mice; Mice, Inbred BALB C; Oseltamivir; Therapeutic Equivalency | 2017 |
Reductive amination assistance for quantification of oseltamivir phosphate and oseltamivir carboxylate by HPLC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Humans; Limit of Detection; Linear Models; Oseltamivir; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
A tetravalent sialic acid-coated tetraphenylethene luminogen with aggregation-induced emission characteristics: design, synthesis and application for sialidase activity assay, high-throughput screening of sialidase inhibitors and diagnosis of bacterial va
Topics: Adult; Clostridium perfringens; Enzyme Inhibitors; Female; Fluorescence; Fluorescent Dyes; Fluorometry; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Limit of Detection; Middle Aged; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Sialic Acids; Stilbenes; Vaginosis, Bacterial; Vibrio cholerae; Young Adult; Zanamivir | 2018 |
Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate.
Topics: Administration, Intravenous; Animals; Male; Oseltamivir; Phosphates; Prodrugs; Rats; Rats, Sprague-Dawley | 2019 |
Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys.
Topics: Animals; Antiviral Agents; Dose-Response Relationship, Drug; Female; Injections, Intravenous; Intubation, Gastrointestinal; Macaca mulatta; Molecular Conformation; Oseltamivir; Phosphorous Acids; Pregnancy | 2020 |
Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.
Topics: Adult; Age Factors; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Infant; Infant, Newborn; Kidney; Male; Models, Biological; Oseltamivir | 2020 |
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Computer Simulation; Enzyme Inhibitors; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Oseltamivir; Prodrugs; Young Adult | 2020 |
Metabolism and disposition of oseltamivir (OS) in rats, determined by immunohistochemistry with monospecific antibody for OS or its active metabolite oseltamivir carboxylate (OC): A possibility of transporters dividing the drugs' excretion into the bile a
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antiviral Agents; Bile; Female; Immunohistochemistry; Kidney; Liver; Male; Mice; Mice, Inbred BALB C; Oseltamivir; Prodrugs; Rats; Rats, Wistar; Tissue Distribution | 2020 |
Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Glycoside Hydrolases; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Structure-Activity Relationship | 2023 |
An oseltamivir-resistant avian H1N1 influenza A virus can transmit from mallards to chickens similarly to a wild-type strain: implications for the risk of resistance transmission to humans.
Topics: Animals; Antiviral Agents; Chickens; Drug Resistance, Viral; Ducks; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir | 2023 |
A novel
Topics: Glycoside Hydrolases; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Molecular Docking Simulation; Neuraminidase; Oseltamivir | 2023 |